Barbara Lavery

During her career, Barbara has been involved in every type of communications assignment, including issues management, awareness building, internal communications & stakeholder relations, media & investor relations, pre-approval and new product approval support, corporate and brand positioning, events management & meeting support, advocacy and KOL relations, and digital and social media strategies. She has provided strategic and tactical counsel for clients such as Gilead, Regeneron, Novartis, Celgene, ARIAD, Seattle Genetics, Array Biopharma, Dynavax, Medtronic, Sequenom, Smith & Nephew, GlobalGenes, FasterCures (Milken Foundation), Dr Susan Love Foundation, The Epilepsy Foundation, The Parkinsons Disease Foundation and many leading publicly traded biotech companies & non-profits over the last decade. She has significant experience working with oncology and rare disease companies. She has served as a company President, non-profit board chair, business development leader, creative director, strategist, writer and editor while always challenging the status quo. Barbara co-wrote the proposal to bring the California Institute for Regenerative Medicine to San Francisco and has served as a consultant to BIO, BayBio, Janssen and the San Francisco Mayor’s Office. She has been a vocal advocate for the role of patients in the development of new medicines and constantly looked for new more effective models & communications to bring better health and awareness to everyone. Having spent 18 years growing and leading a company, Barbara joined the non-profit world as Board Chair of Global Genes – a leading rare disease advocacy organization. Barbara has presented at myriad industry conferences and forums including BIO, NIH, Keck Graduate Institute, JLABS, California Life Sciences Association, Xconomy, BioPartnering Europe, Partnering for Cures, C21 Bioventures, New Paradigms. She is a graduate of the Annenberg Foundation Alchemy+ program.